Interações de Rizatriptana

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Anfetamina, Advertências e precauções)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (bula de Anfetamina + dextroanfetamina, Advertências e precauções)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Beladona + ópio, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Buprenorfina, Interações medicamentosas)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Buprenorfina + naloxona, Interações medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (bula de Buspirona, Advertências)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Butalbital + paracetamol + cafeína + codeína, Interações medicamentosas)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Butorfanol, Precauções)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

Immediately discontinue concomitant treatment with TONMYA and a serotonergic agent if serotonin syndrome symptoms occur and initiate supportive symptomatic treatment. (bula de Ciclobenzaprina, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Codeína, Interações medicamentosas)

Concomitant use of Monoamine Oxidase Inhibitors (MAOIs) and serotonergic drugs may potentially cause life threatening adverse events ( see CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION ). (bula de Desipramina, Interações medicamentosas)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Desvenlafaxina, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (bula de Dextroanfetamina, Advertências)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (bula de Duloxetina, Advertências e precauções)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

Combinar a erva-de-são-joão (hipérico) com antidepressivos e outros medicamentos serotoninérgicos aumenta o risco de síndrome serotoninérgica. (NCCIH, St. John's Wort)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Fentanila, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (bula de Granisetrona, Advertências e precauções)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona, Interações medicamentosas)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + clorfeniramina, Interações medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidrocodona + homatropina, Interações medicamentosas)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + ibuprofeno, Precauções)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Hidrocodona + paracetamol, Precauções)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Hidromorfona, Interações medicamentosas)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Levomilnaciprana, Advertências e precauções)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Levorfanol, Precauções)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Lisdexanfetamina, Advertências e precauções)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (bula de Lítio, Advertências e precauções)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Metadona, Advertências e precauções)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (bula de Metanfetamina, Advertências e precauções)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (bula de Metaxalona, Interações medicamentosas)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (bula de Rizatriptana, Contraindicações)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Milnaciprana, Advertências e precauções)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (bula de Mirtazapina, Advertências e precauções)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (bula de Morfina, Interações medicamentosas)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oliceridina, Interações medicamentosas)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (bula de Ondansetrona, Advertências e precauções)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (bula de Oxicodona, Interações medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Oximorfona, Interações medicamentosas)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (bula de Palonosetrona, Advertências e precauções)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Paracetamol + codeína, Precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (bula de Pentazocina + naloxona, Precauções)

‎ • Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Petidina (meperidina), Advertências e precauções)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (bula de Prometazina + codeína, Interações medicamentosas)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Remifentanila, Advertências e precauções)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (bula de Tapentadol, Advertências e precauções)

Monoamine Oxidase Inhibitors MAXALT is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. (bula de Rizatriptana, Interações medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (bula de Trazodona, Advertências e precauções)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (bula de Venlafaxina, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (bula de Vortioxetina, Advertências e precauções)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (bula de Ziprasidona, Advertências e precauções)

Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or of an ergotamine-containing medication ( 4 ) (bula de Rizatriptana, Contraindicações)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

SSRIs/SNRIs and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7) ] . (bula de Rizatriptana, Interações medicamentosas)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

Drugs that Increase Blood Pressure Administering NORTHERA in combination with other agents that increase blood pressure (e.g., norepinephrine, ephedrine, midodrine, and triptans) would be expected to increase the risk for supine hypertension. (bula de Droxidopa, Interações medicamentosas)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (bula de Rizatriptana, Interações medicamentosas)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (bula de Rizatriptana, Interações medicamentosas)

Nadolol/Metoprolol : In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n=12). (bula de Rizatriptana, Interações medicamentosas)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (bula de Nalbufina, Interações medicamentosas)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

Propranolol The dose of MAXALT should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ] . (bula de Rizatriptana, Interações medicamentosas)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (bula de Rizatriptana, Advertências e precauções)

Serotonin Syndrome Risk: Potentially life-threatening condition could result from use of Tramadol Hydrochloride Extended-Release Capsules, particularly during concomitant use of serotonergic drugs. (bula de Tramadol, Advertências e precauções)

Serotonin Syndrome Risk Cases of serotonin syndrome, a potentially life-threatening condition, have been reported with the use of tramadol, including tramadol hydrochloride and acetaminophen, during concomitant use with serotonergic drugs. (bula de Tramadol + paracetamol, Advertências e precauções)

The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. (bula de Rizatriptana, Advertências e precauções)

SSRIs/SNRIs and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) [see Warnings and Precautions (5.7) ] . (bula de Rizatriptana, Interações medicamentosas)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (bula de Rizatriptana, Advertências e precauções)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (bula de Fentermina, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Serotonin Syndrome Serotonin syndrome may occur with triptans, including MAXALT particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors [see Drug Interactions (7.5) ] . (bula de Rizatriptana, Advertências e precauções)

Medication Overuse Headache Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). (bula de Rizatriptana, Advertências e precauções)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)

Oral contraceptives : In a study of concurrent administration of an oral contraceptive during 6 days of administration of MAXALT (10-30 mg/day) in healthy female volunteers (n=18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone. (bula de Rizatriptana, Interações medicamentosas)